Author: admin

Age-related Vision Dysfunction Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

DelveInsight’s “Age-related Vision Dysfunction Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Age-related Vision Dysfunction, historical and forecasted epidemiology as well as the Age-related Vision Dysfunction market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock key insights into the Age-related Vision Dysfunction Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Age-related Vision Dysfunction Market Size

 

Key Takeaways from the Age-related Vision Dysfunction Market Report

  • As per DelveInsight estimates, the cases of presbyopia are the highest among all the considered etiologies of in the 7MM.
  • The United States accounted for more than 35% of cases of Wet-Age-related Macular Degeneration in the 7MM.
  • The United States accounted for the highest prevalent cases of Glaucoma in the year 2023.
  • As per DelveInsight estimates, Japan accounted for 50% of total Diagnosed prevalent cases of Presbyopia in 2023..
  • The leading Age-related Vision Dysfunction Companies such as Hoffman La Roche, MicroLine, AbbVie, Regenxbio, Novartis, Santen, Nicox Ophthalmics, Kodiak Sciences, Opthea Limited, Ocular Therapeutix, Orasis Pharmaceuticals, IVERIC bio, Alkeus Pharmaceuticals, Outlook Therapeutics, Sun Pharma Advanced Research Company Limited, and many others.
  • Promising Age-related Vision Dysfunction Therapies such as bevacizumab, Rocklatan (Latanoprast; Netarsudil Dimesylate), Eybelis Ophthalmic Solution (DE-117, Omidenepag isopropyl), Xelpros (Latanoprost Ophthalmic Emulsion), and others.

 

Stay ahead in the competitive landscape of the Age-related Vision Dysfunction Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Age-related Vision Dysfunction Treatment Market Size

 

Age-related Vision Dysfunction Epidemiology Segmentation in the 7MM

  • Total Age-related Vision Dysfunction Prevalent Cases
  • Total Age-related Vision Dysfunction Diagnosed Prevalent Cases
  • Age-related Vision Dysfunction Type-specific Diagnosed Prevalent Cases
  • Age-related Vision Dysfunction Severity-specific Diagnosed Prevalent Cases
  • Total Age-related Vision Dysfunction Treatable Cases

 

Download the report to understand which factors are driving Age-related Vision Dysfunction epidemiology trends @ Age-related Vision Dysfunction Prevalence

 

Age-related Vision Dysfunction Marketed Drugs

• VABYSMO: Genentech

VABYSMO (faricimab-svoa) is a prescription medicine, developed by Genentech, given by injection into the eye used to treat adults with neovascular (wet) Age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. VABYSMO was first approved in the US by the FDA in January 2022, targets and inhibits two disease pathways that drive wet Age-related macular degeneration and diabetic macular edema and is now available in multiple countries, including Europe. In October 2023, Roche received a new indication approval by FDA for the use of VABYSMO to treat macular edema following retinal vein occlusion.

 

• LUCENTIS: Genentech

LUCENTIS (ranibizumab injection) is a prescription medicine, developed by Genentech for the treatment of patients with wet Age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, myopic choroidal neovascularization. In April 2017, FDA Approves Genentech’s LUCENTIS (ranibizumab Injection) for Diabetic Retinopathy, the leading cause of blindness among working age adults in the United States. It was the first and only medicine FDA-approved to treat all forms of diabetic retinopathy and Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of Health (NIH)-funded collaborative group study.

 

Age-related Vision Dysfunction Emerging Drugs

• KSI-301 (tarcocimab tedromer): Kodiak Sciences Inc.

Kodiak Science’s KSI-301 is a novel anti-Vascular endothelial growth factor biologic designed to rapidly inhibit Vascular endothelial growth factor and provide extended durability of action to reduce the burden of frequent anti-Vascular endothelial growth factor injections. Delivering potent and sustained vascular endothelial growth factor inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes. The drug has recently completed its phase III study. The biologic is also in Phase III for Diabetic Macular Edema, Diabetic retinopathy, Tetinal Vein Occlusion, and Triplet Inhibitor for dry Age-related Macular Degeneration. KSI-301 is administered as an intravitreal injection and designed to provide sustained inhibition of vascular endothelial growth factor for up to 6 months.

 

• ONS-5010/LYTENAVA: Outlook Therapeutics

Outlook Therapeutics’ ONS-5010/LYTENAVA is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet Age-related Macular Degeneration and other retinal diseases. ONS-5010 is a full-length, humanized anti-Vascular endothelial growth factor recombinant monoclonal antibody (mAb) that inhibits vascular endothelial growth factor and associated angiogenic activity

 

Discover the future of Age-related Vision Dysfunction Treatments with DelveInsight’s latest market report. Get expert insights and forecasts—download now! @ Age-related Vision Dysfunction Market Drivers and Barriers

 

Age-related Vision Dysfunction Therapies and Companies

  • AGN-190584 (Allergan [acquired by AbbVie])
  • MicroLine/Pilocarpine Ophthalmic (Eyenovia)
  • PresbiDrops/CSF-1 (Orasis Pharmaceuticals)
  • Zimura/ Avacincaptad pegol (IVERIC Bio)
  • ALK-001 (Alkeus Pharmaceuticals)
  • ONS-5010/Lytenava/Bevacizumab-vikg (Outlook Therapeutics)
  • KSI-301 (Kodiak Sciences)
  • Faricimab (Roche)
  • Abicipar (Allergan [acquired by AbbVie]/Molecular Partners)
  • RGX-314 (Regenxbio)
  • Beovu/RTH258/Brolucizumab (Novartis)
  • STN1013001/DE-130A/Catioprost and latanoprost emulsion (Santen SAS)
  • NCX 470 (Nicox Ophthalmics)
  • OTX-TP/Travoprost ophthalmic insert (Ocular Therapeutix)
  • PDP-716 (Sun Pharma Advanced Research Company Limited)
  • OPT-302 (Opthea)
  • Lumitin/Conbercept (Chengdu Kanghong Pharmaceuticals)
  • AKST4290/Lazucirnon (Alkahest)
  • GT005 (Gyroscope Therapeutics)
  • ADVM-022 (Adverum Biotechnologies)
  • Emixustat hydrochloride (Kubota Vision)
  • KVD001 (KalVista Pharmaceuticals)
  • Luminate/ALG-1001/Risuteganib (Allergo Opthalmics and Baush Health)
  • GB-102 (Graybug Vision)
  • Razuprotafib/AKB-9778 (Aerpio Pharmaceuticals)
  • Nyxol/Phentolamine Mesylate (Ocuphire Pharma)
  • STN1012600/DE-126 (Santen Pharmaceutical)

 

Age-related Vision Dysfunction Market Outlook

The Age-related Vision Dysfunction market outlook reflects a dynamic landscape characterized by a growing demand for innovative treatments and technologies to address the diverse needs of aging populations worldwide. With approximately one in three individuals experiencing some form of vision-reducing eye disease by the age of 65, the prevalence of conditions such as Age-related macular degeneration, glaucoma, cataracts, diabetic retinopathy, and refractive errors underscores the urgent need for effective therapeutic interventions.

 

Explore the dynamics of the Age-related Vision Dysfunction Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Age-related Vision Dysfunction Ongoing Clinical Trials Analysis

 

Scope of the Age-related Vision Dysfunction Market Report

  • Coverage- 7MM
  • Study Period- 2020-2034
  • Age-related Vision Dysfunction Companies- Hoffman La Roche, MicroLine, AbbVie, Regenxbio, Novartis, Santen, Nicox Ophthalmics, Kodiak Sciences, Opthea Limited, Ocular Therapeutix, Orasis Pharmaceuticals, IVERIC bio, Alkeus Pharmaceuticals, Outlook Therapeutics, Sun Pharma Advanced Research Company Limited, and many others.
  • Age-related Vision Dysfunction Therapies- bevacizumab, Rocklatan (Latanoprast; Netarsudil Dimesylate), Eybelis Ophthalmic Solution (DE-117, Omidenepag isopropyl), Xelpros (Latanoprost Ophthalmic Emulsion), and others.
  • Age-related Vision Dysfunction Market Dynamics: Age-related Vision Dysfunction Market drivers and Age-related Vision Dysfunction Market Barriers
  • Age-related Vision Dysfunction Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Age-related Vision Dysfunction Unmet Needs, KOL’s views, Analyst’s views, Age-related Vision Dysfunction Market Access and Reimbursement

 

Table of Content

1 Key Insights

2 Report Introduction

3 Executive Summary

4 Key Events

5 Epidemiology and Market Forecast Methodology

6 Age-related Vision Dysfunction Market Overview at a Glance

7 Disease Background and Overview of Age-related Vision Dysfunction

8 Treatment and Management

9 Epidemiology and Patient Population of Age-related Vision Dysfunction

10 Patient Journey

11 Marketed Drugs

12 Emerging Drugs

13. Age-related Vision Dysfunction: Seven Major Market Analysis

14 Unmet Needs

15 SWOT Analysis

16 KOL Views

17 Market Access and Reimbursement

18 Appendix

19 DelveInsight Capabilities

20 Disclaimer

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/lactose-intolerance-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Age-related Vision Dysfunction Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

Alpha Thalassemia Pipeline 2024: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharma

//(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Alpha Thalassemia pipeline constitutes 4+ key companies continuously working towards developing 5+ Alpha Thalassemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

The Alpha Thalassemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Alpha Thalassemia Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alpha Thalassemia Market.

 

Some of the key takeaways from the Alpha Thalassemia Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Alpha Thalassemia treatment therapies with a considerable amount of success over the years.

  • Alpha Thalassemia companies working in the treatment market are Forma Therapeutics, Inc., Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharmaceuticals, and others, are developing therapies for the Alpha Thalassemia treatment

  • Emerging Alpha Thalassemia therapies in the different phases of clinical trials are- Etavopivat tablets, GMCN-508A, Luspatercept, Mitapivat, and others are expected to have a significant impact on the Alpha Thalassemia market in the coming years.

  • In January 2025, Agios Pharmaceuticals (AGIO) revealed that the FDA has accepted its supplemental New Drug Application (sNDA) for PYRUKYND® (mitapivat) as a treatment for adult patients with both transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia. The FDA has granted the application a standard review designation, setting a target decision date of September 7, 2025, under the Prescription Drug User Fee Act (PDUFA).

  • In December 2024, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation, which is pioneering therapies for rare diseases, today announced positive results from the Phase 3 ENERGIZE-T study of mitapivat, an oral small-molecule PK activator, in adults with transfusion-dependent alpha- or beta-thalassemia. These results were presented in an oral session (abstract #409) at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) in San Diego, California.

  • In July 2024, Researchers from Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine have developed an innovative model that could serve as a platform for creating new therapies to treat Alpha Thalassemia (AT), a serious blood disorder. Their findings were published in the journal Blood. Each year, thousands of children are born with AT, particularly in regions like Southeast Asia, India, the Middle East, and the Mediterranean. While the genetic trait can offer protection against malaria and cause only mild anemia in its normal form, children whose parents both carry defective genes face a significantly higher risk of severe AT.

  • In January 2024, Agios Pharmaceuticals reported positive outcomes in a Phase III ENERGIZE trial of mitapivat for patients with non-transfusion-dependent alpha- or beta-thalassemia, meeting primary and two key secondary endpoints. The company intends to seek regulatory approval for mitapivat as a thalassemia treatment by year-end, incorporating data from the second Phase III ENERGISE-T study (NCT04770779) for adults with transfusion-dependent alpha-thalassemia or beta-thalassemia.

 

Alpha Thalassemia Overview

Alpha thalassemia is a genetic disorder characterized by a deficiency in the production of alpha globin chains, which are essential components of hemoglobin, the protein in red blood cells that carries oxygen throughout the body. This deficiency results in a reduced amount of hemoglobin and red blood cells, leading to anemia.

 

Get a Free Sample PDF Report to know more about Alpha Thalassemia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/alpha-thalassemia-pipeline-insight-pipeline-insight

 

Emerging Alpha Thalassemia Drugs Under Different Phases of Clinical Development Include:

  • Etavopivat tablets: Forma Therapeutics, Inc.

  • GMCN-508A: Genmedicn Biopharma Ltd.

  • Luspatercept: Bristol-Myers Squibb

  • Mitapivat: Agios Pharmaceuticals

 

Alpha Thalassemia Route of Administration

Alpha Thalassemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Alpha Thalassemia Molecule Type

Alpha Thalassemia Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

 

Alpha Thalassemia Pipeline Therapeutics Assessment

  • Alpha Thalassemia Assessment by Product Type

  • Alpha Thalassemia By Stage and Product Type

  • Alpha Thalassemia Assessment by Route of Administration

  • Alpha Thalassemia By Stage and Route of Administration

  • Alpha Thalassemia Assessment by Molecule Type

  • Alpha Thalassemia by Stage and Molecule Type

 

DelveInsight’s Alpha Thalassemia Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Alpha Thalassemia product details are provided in the report. Download the Alpha Thalassemia pipeline report to learn more about the emerging Alpha Thalassemia therapies

 

Alpha Thalassemia Pipeline Analysis:

The Alpha Thalassemia pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Alpha Thalassemia with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alpha Thalassemia Treatment.

  • Alpha Thalassemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Alpha Thalassemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alpha Thalassemia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Alpha Thalassemia drugs and therapies

 

Alpha Thalassemia Pipeline Market Drivers

  • Increasing Prevalence genetic disorders and advancement in healthcare technologies, growing demand for treatment for Alpha Thalassemia are some of the important factors that are fueling the Alpha Thalassemia Market.

 

Alpha Thalassemia Pipeline Market Barriers

  • However, lack of available appropriate treatments and procedures, high cost of treatment and other factors are creating obstacles in the Alpha Thalassemia Market growth.

 

Scope of Alpha Thalassemia Pipeline Drug Insight

  • Coverage: Global

  • Key Alpha Thalassemia Companies: Forma Therapeutics, Inc., Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharmaceuticals, and others

  • Key Alpha Thalassemia Therapies: Etavopivat tablets, GMCN-508A, Luspatercept, Mitapivat, and others

  • Alpha Thalassemia Therapeutic Assessment: Alpha Thalassemia current marketed and Alpha Thalassemia emerging therapies

  • Alpha Thalassemia Market Dynamics: Alpha Thalassemia market drivers and Alpha Thalassemia market barriers

 

Request for Sample PDF Report for Alpha Thalassemia Pipeline Assessment and clinical trials

 

Table of Contents

1. Alpha Thalassemia Report Introduction

2. Alpha Thalassemia Executive Summary

3. Alpha Thalassemia Overview

4. Alpha Thalassemia- Analytical Perspective In-depth Commercial Assessment

5. Alpha Thalassemia Pipeline Therapeutics

6. Alpha Thalassemia Late Stage Products (Phase II/III)

7. Alpha Thalassemia Mid Stage Products (Phase II)

8. Alpha Thalassemia Early Stage Products (Phase I)

9. Alpha Thalassemia Preclinical Stage Products

10. Alpha Thalassemia Therapeutics Assessment

11. Alpha Thalassemia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Alpha Thalassemia Key Companies

14. Alpha Thalassemia Key Products

15. Alpha Thalassemia Unmet Needs

16 . Alpha Thalassemia Market Drivers and Barriers

17. Alpha Thalassemia Future Perspectives and Conclusion

18. Alpha Thalassemia Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alpha Thalassemia Pipeline 2024: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharma

Adeno-Associated Virus Vectors in Gene Therapy Therapeutics Market Size in the 7MM is expected to increase by 2034, estimates DelveInsight

DelveInsight’s “Adeno-Associated Virus Vector in Gene Therapy Market Insights, Epidemiology, and Market Forecast–2034” report delivers an in-depth understanding of Adeno-Associated Virus Vector in Gene Therapy, historical and forecasted epidemiology as well as Adeno-Associated Virus Vector in Gene Therapy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Unlock key insights into the Adeno-Associated Virus Vectors in Gene Therapy Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Adeno-Associated Virus Vectors in Gene Therapy Market Size

 

Key Takeaways from the Adeno-Associated Virus Vectors in Gene Therapy Market Report

  • In January 2025:- MeiraGTx UK II Ltd:- Phase 1 of the study is a dose escalation of the subretinal administration of AAV5-hRKp.RPGR vector to assess the safety of this vector in participants with XLRP caused by mutations in RPGR. Participants enrolled in Phase 1 were assigned to a dose group based on when they enrolled (i.e., sequential assignment).
  • In January 2025:- Janssen Pharmaceuticals Inc.:- The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.
  • In January 2025:- CSL Behring:- Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B.
  • Retinitis Pigmentosa, is the leading cause of visual disability and blindness in subjects less than 60 years old.
  • Hemophilia A is more common than Hemophilia B, representing approximately 80–85% of the total hemophilia population.
  • The leading Adeno-Associated Virus Vectors in Gene Therapy Companies such as Biomarin Pharmaceutical, Sarepta Therapeutics, Roche (Spark Therapeutics), Sangamo, Pfizer, NightstaRx, Freeline Therapeutics, Horama S.A, MeiraGTx, RegenxBio, Asklepios Biopharmaceutical, Audentes Therapeutics, and others.
  • Promising Adeno-Associated Virus Vectors in Gene Therapy Therapies such as BMN 307, AAV9 BBP-812, GS-100, RP-A501, AAV5-hFIXco-Padua, AB-1001 Gene Therapy, and others.

 

Stay ahead in the competitive landscape of the Adeno-Associated Virus Vectors in Gene Therapy Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Adeno-Associated Virus Vectors in Gene Therapy Treatment Market Size

 

Adeno-Associated Virus Vectors in Gene Therapy Epidemiology Segmentation in the 7MM

• Total Prevalent Cases of Selected Indications

• Total Diagnosed Prevalent Cases of Selected Indications

• Total Treated Cases of Selected Indications

 

Download the report to understand which factors are driving Adeno-Associated Virus Vectors in Gene Therapy epidemiology trends @ Adeno-Associated Virus Vectors in Gene Therapy Prevalence

 

Adeno Associated Virus Vectors in Gene Therapy Marketed Drugs

• LUXTURNA: Spark Therapeutics

LUXTURNA (voretigene neparvovec-rzyl) is a suspension of an adeno-associated virus vector-based gene therapy for subretinal injection. LUXTURNA is a live, non-replicating adeno-associated virus serotype 2 which has been genetically modified to express the human RPE65 gene. LUXTURNA is derived from naturally occurring adeno-associated virus using recombinant DNA techniques. LUXTURNA, is a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65 gene. The FDA approved Spark Therapeutics’ LUXTURNA in December 2017.

 

• ZOLGENSMA: Novartis

ZOLGENSMA is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. It is a recombinant self-complementary AAV9 containing a transgene encoding the human survival motor neuron (SMN) protein, under the control of a cytomegalovirus enhancer/chicken-β-actin hybrid promoter. ZOLGENSMA an AAV-delivered gene therapy used to treat spinal muscular atrophy (SMA), was approved for clinical use in the US by the FDA.

 

Adeno Associated Virus Vectors in Gene Therapy Emerging Drugs

• LUMEVOQ: GenSight Biologics

LUMEVOQ (GS010; lenadogene nolparvovec) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, arising from research conducted at the Institut de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically address defects inside the mitochondria using an AAV vector. According to Phase III results all treated participants showed sustained improvement over 4 years, but that patients treated with a bilateral injection of the gene therapy continued to have a better visual acuity than the patients treated with a unilateral injection, a disparity that had been seen in REFLECT since 1.5 years posttreatment. The company is planning to submit to MHRA in the second half of 2024 and aiming to receive a decision from MHRA on LUMEVOQ in the second half of 2025, in the hopes of commercializing the product in the UK that same year.

 

• Giroctocogene fitelparvovec: Sangamo and Pfizer

Giroctocogene fitelparvovec comprises of a recombinant AAV6 encoding the complementary deoxyribonucleic acid for B-domain deleted human FVIII. It is being developed as part of a collaboration agreement for the global development and commercialization of gene therapies for hemophilia A between Sangamo and Pfizer. Currently, the company is conducting Phase III trials to attain better and clear results about the efficacy of SB-525. A Phase III clinical trial (NCT03587116) evaluates the effectiveness and safety of preventive replacement therapy in the usual care setting in hemophilia A patients. A pivotal readout is expected in mid-2024, with Pfizer anticipating BLA and MAA submissions in the second half of 2024 if the pivotal readout is supportive.

 

Discover the future of Adeno-Associated Virus Vectors in Gene Therapy Treatments with DelveInsight’s latest market report. Get expert insights and forecasts—download now! @ Adeno-Associated Virus Vectors in Gene Therapy Market Drivers and Barriers

 

Adeno-Associated Virus Vector in Gene Therapy Market Outlook

Adeno Associated Virus Vectors in Gene Therapy has provided a unique opportunity to treat and even cure degenerative diseases, offering hope to the millions of people either affected by inherited disorders or carrying disease-causing mutations. Addressing optimal intervention timing, standardized outcome assessments, inflammation mitigation, awareness enhancement, and equitable access are key to advancing inherited retinal disease treatments and reshaping the landscape of visual impairment. Gene therapies have brought about a change in the treatment paradigm for genetic diseases by providing lasting therapeutic effects with a single intervention. Gene therapy holds significant potential for addressing various eye diseases.

 

Adeno-Associated Virus Vectors in Gene Therapy Drug Market

The report provides insights into therapeutic candidates in Phase III, Phase II/III, and Phase II. It also analyzes key players involved in developing targeted therapeutics. Companies like Sangamo and Pfizer, MEIRAGTx/J&J, Johnson & Johnson, and others actively engage in late and mid-stage research and development efforts for Adeno-Associated Virus Vector in Gene Therapy pipeline possesses potential drugs. However, there is a positive outlook for the therapeutics market, with expectations of growth during the forecast period (2024–2034).

 

Explore the dynamics of the Adeno-Associated Virus Vectors in Gene Therapy Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Adeno-Associated Virus Vectors in Gene Therapy Ongoing Clinical Trials Analysis

 

Scope of the Adeno-Associated Virus Vectors in Gene Therapy Market Report

  • Coverage- 7MM
  • Study Period- 2020-2034
  • Adeno-Associated Virus Vectors in Gene Therapy Companies- Biomarin Pharmaceutical, Sarepta Therapeutics, Roche (Spark Therapeutics), Sangamo, Pfizer, NightstaRx, Freeline Therapeutics, Horama S.A, MeiraGTx, RegenxBio, Asklepios Biopharmaceutical, Audentes Therapeutics, and others.
  • Adeno-Associated Virus Vectors in Gene Therapy Therapies- BMN 307, AAV9 BBP-812, GS-100, RP-A501, AAV5-hFIXco-Padua, AB-1001 Gene Therapy, and others.
  • Adeno-Associated Virus Vectors in Gene Therapy Market Dynamics: Adeno-Associated Virus Vectors in Gene Therapy Market Drivers and Barriers
  • Adeno-Associated Virus Vectors in Gene Therapy Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Table of Content

1 Key Insights

2 Report Introduction

3 Key Highlights from Report

4 Executive Summary of AAV in Gene Therapy

5 Key Events

6 Epidemiology and Market Forecast Methodology

7 AAV in Gene Therapy Market Overview at a Glance in the 7MM

8 Disease Background and Overview

9 Epidemiology and Patient Population

10 Marketed Drugs

11 Emerging Drugs

12 AAV in Gene Therapy: 7MM analysis

13 Unmet Needs

14 SWOT Analysis

15 KOL Views

16 Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Adeno-Associated Virus Vectors in Gene Therapy Therapeutics Market Size in the 7MM is expected to increase by 2034, estimates DelveInsight

Dental Impression Systems Market Growing Trends, Future Outlook, Advance Technology, Global Size, Share And Forecast

“3M (US), Henry Schein (US), Dentsply Sirona (US), Mitsui Chemicals (Japan), and Envista (US) are the key players operating in the dental impression systems market. Other prominent players in this market include Parkell, Inc. (US)”
Browse 121 market data Tables and 38 Figures spread through 171 Pages and in-depth TOC on “Dental Impression Systems Market by Product (Impression Material, Intraoral Scanners, Trays), Application (Restorative and Prosthodontics Dentistry, Orthodontics), End User (Hospitals, Dental Laboratories, Forensic Laboratories) – Global Forecast to 2025

According to the new market research report “Dental Impression Systems Market by Product (Impression Material, Intraoral Scanners, Trays), Application (Restorative and Prosthodontics Dentistry, Orthodontics), End User (Hospitals, Dental Laboratories, Forensic Laboratories) – Global Forecast to 2025″, published by MarketsandMarkets™, the Dental Impression Systems Market is projected to reach USD 1.9 billion by 2025 from USD 1.3 billion in 2020, at a CAGR of 7.7% during the forecast period.

Browse in-depth TOC on “Dental Impression Systems Market”

121 – Tables

38 – Figures

171 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=256609208

The growth of this market is majorly attributed to the rising incidence of dental diseases and increasing demand for cosmetic dentistry. Also, growing dental tourism in emerging markets and rising adoption of digital dentistry are expected to drive demand growth in the dental impression systems market during the forecast period.

By product, segment, the intraoral scanners segment is expected to grow at the highest growth rate during the forecast period

Among the product, segment, the intraoral scanners segment is expected to grow at the highest CAGR during the forecast period. The intraoral scanners segment is estimated to grow at the highest CAGR during the forecast period as these scanners increase the accuracy of dental impressions and reduce the time involved in procedures.

By application, the restorative and prosthodontics dentistry segment is expected to account for the largest share of the dental impression systems market

The restorative and prosthodontics dentistry segment accounted for the largest share of the global dental impression systems market in 2019. Growth in the edentulous population and the increasing number of patients suffering from dental problems are driving the growth of this application segment.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=256609208

By end user, the dental hospitals and clinics segment is expected to account for the largest share of the dental impression systems market

Based on end user, the dental impression systems market is segmented into dental hospitals and clinics, dental laboratories, dental academics and research institutes, and forensic laboratories. The increasing number of dental clinics and hospitals across the globe and the rapid adoption of advanced technologies by small and large dental clinics and hospitals are the major factor driving the growth of dental hospitals and clinics segment.

Europe dominates the Dental impression systems market during the forecast period

Europe accounted for the largest share of the Dental impression systems market in 2019. The growing popularity of cosmetic dentistry, high and growing demand for technologically advanced products, increasing availability and use of intraoral scanners, and the rising incidence of dental diseases are some of the factors driving the growth of the dental impression systems market in this region.

3M (US), Henry Schein (US), Dentsply Sirona (US), Mitsui Chemicals (Japan), and Envista (US) are the key players operating in the dental impression systems market. Other prominent players in this market include Parkell, Inc. (US), Kettenbach GmbH & Co. KG (Germany), Zest Dental Solutions (US), Keystone Industries (US), Ultradent Products, Inc. (US), Septodont Holding (US), GC Corporation (US), DETAX (Germany), Kerr Corporation (US), Ivoclar Vivadent (US), Kuraray Co. Ltd. (Japan), BEGO (Germany), Premier Dental Products Company (US), and DMG America (US).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=256609208

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/dental-impression-system-market-256609208.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dental Impression Systems Market Growing Trends, Future Outlook, Advance Technology, Global Size, Share And Forecast

Interior Fit Out Market is Anticipated to Reach $89.15 Bn by 2029 | CAGR of 5.41% – Arizton

“Interior Fit Out Market Research Report by Arizton”

 

According to Arizton’s latest research report, the interior fit out market is growing at a CAGR of 5.41% during 2023-2029.

          

Looking for More Information? Click: https://www.arizton.com/market-reports/interior-fit-out-market

 

Report Scope:          

Market Size (2029): $89.15 Billion 

Market Size (2023): $65 Billion  

CAGR (2023-2029): 5.41% 

Historic Year: 2020-2022     

Base Year: 2023       

Forecast Year: 2024-2029     

Market Segmentation: Service, Project Type, Budget, Style, End-Users, and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa

 

Interior Fit Out Market Overview

The global interior fit-out market is experiencing steady growth. As urbanization increases and consumer preferences evolve, there is a rising need for interior spaces that combine aesthetics, functionality, and space optimization.

In the commercial sector, flexible working arrangements have boosted demand for adaptable designs that enhance productivity. The retail sector is adapting to the rise of e-commerce by focusing on immersive shopping experiences that attract customers through high-quality fit-outs. Residential consumers are increasingly seeking personalized interiors that reflect their individual tastes, while the hospitality sector emphasizes unique, aesthetically pleasing spaces to create memorable guest experiences. The market includes services such as construction and installation, design and consultation, and ongoing maintenance and project management. These services play a vital role in ensuring that spaces are not only well-designed but also functional and long-lasting.

Geographically, North America leads due to strong economic growth and sustainability trends, while Europe is known for its diverse architectural styles and innovative designs. The APAC region is experiencing rapid growth, driven by urbanization and a rising middle class, with countries like China and India playing a key role. The Middle East, especially the UAE, is also seeing growth due to high-profile construction projects in hospitality and retail.

 

Transforming Commercial Spaces: The Future of Interior Fit-Outs

The commercial interior fit-out market is experiencing a surge in demand. Businesses are increasingly focused on creating environments that enhance productivity, attract customers, and reinforce brand identity. Key trends like hybrid work models, experiential retail, and sustainable design are pushing the boundaries of interior fit-outs.

The rise of hybrid workspaces is redefining office layouts, with companies seeking adaptable, multifunctional spaces that encourage collaboration, innovation, and employee well-being. Traditional office designs are being replaced with dynamic workspaces that feature open-plan areas, focus zones, ergonomic workstations, and smart technology integration, creating flexible environments suited to a more dispersed workforce.

For instance, leading companies like Google are embracing redesigns that incorporate wellness zones and collaborative spaces, using sustainable materials to align with their environmental goals. This shift reflects the growing demand for interior fit-out services that not only meet functional needs but also reflect evolving business values and trends. As these transformations continue, the commercial interior fit-out market is set to expand and adapt to the ever-changing landscape of the modern workplace.

 

APAC Interior Fit-Out Market: Driven by Urbanization and Evolving Workspaces

The interior fit-out market in the Asia-Pacific (APAC) region is experiencing robust growth, fueled by urban expansion, rising consumer expectations, and growing investments in commercial real estate. Countries like Singapore, Australia, Japan, and Indonesia are key hotspots for fit-out activities, with significant demand for refurbishments in office spaces, hotels, residential properties, and retail stores. The rise of hybrid work models is driving companies to redesign offices, increasing demand for smart office solutions and sustainable materials.

Rapid urbanization in countries such as India is improving living standards and creating opportunities for residential and commercial interior fit-outs. In addition, Vietnam and Indonesia are seeing a rise in retail and mixed-use developments, further propelling market growth. The booming construction sector, driven by infrastructure projects and smart city initiatives, continues to drive demand for modern interior solutions. As the region expands, the APAC interior fit-out market is poised for continued growth.

 

Driving Success in the Interior Fit-Out Market: Key Factors Shaping Competition and Growth

The interior fit-out market is highly competitive, with a mix of global players and regional firms competing across commercial, residential, hospitality, healthcare, and institutional sectors. Large companies with comprehensive project management capabilities compete with smaller, niche firms that offer specialized services, such as high-end residential interiors or sustainable designs. Competition is influenced by project size, scope, regional demand, and the need for long-term contracts with corporate clients, developers, and government institutions.

Innovation plays a key role in differentiation, with firms adopting technologies like BIM, virtual design tools, and IoT integrations to improve processes. Sustainability is also a growing priority, giving eco-friendly companies a competitive edge. Price competitiveness remains crucial in cost-sensitive regions, while design innovation and sustainability take precedence in mature markets.

The global supply chain and material availability are shaping competition, and firms with strong supplier relationships and efficient procurement strategies are better positioned to navigate challenges. Digital marketing and online platforms have transformed how firms attract clients, while specialized services for hybrid workspaces are in demand. Overall, companies must innovate, prioritize customer relationships, and adapt to market trends to stay competitive.

 

Buy this Research @ https://www.arizton.com/market-reports/interior-fit-out-market

 

Key Company Profiles

  • AECOM
  • Aedas
  • Depa Group
  • ISG Plc
  • Turner Construction Company
  • Mace Group
  • Gilbane
  • STO Building Group
  • Stantec
  • Skanska
  • Balfour Beatty
  • DPR Construction
  • Gensler
  • Perkins & Will
  • HOK
  • SGP
  • Timbermark
  • Spacedge
  • JR Interiors
  • Arco Interiors
  • Sense Projects Pvt Ltd
  • Phi Designs
  • Jones Lang LaSalle IP, Inc.
  • Design Infinity
  • Add India Group
  • S&T Interiors and Contracting
  • Zircon
  • Rhino Interiors Group

 

Market Segmentation

 

Service

  • Construction & Installation
  • Design & Consulting
  • Other Services

 

Project Type

  • New Construction
  • Renovation & Refurbishment

 

Budget

  • Economy & Mid-Range
  • Luxury & Premium

 

Style

  • Modern & Contemporary
  • Traditional & Classic
  • Eco-Friendly & Sustainable
  • Other Styles

 

End-Users

  • Commercial
  • Residential
  • Hospitality
  • Healthcare
  • Retail
  • Others

 

Geography

 

APAC

  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Singapore

 

North America

  • The U.S.
  • Canada

 

Europe

  • Germany
  • The U.K.
  • France
  • Italy
  • Spain
  • Netherlands

 

Middle East & Africa

  • The UAE
  • Saudi Arabia
  • South Africa
  • Qatar

 

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Chile

     

What Key Findings Will Our Research Analysis Reveal?        

How big is the global interior fit out market?

What is the growth rate of the global interior fit out market?

Which region dominates the global interior fit out market share?

What are the significant trends in the interior fit out industry?

Who are the key players in the global interior fit out market?

        

Other Related Reports that Might be of Your Business Requirement        

Prefabricated Interior Staircase Market – Global Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/prefabricated-interior-staircase-market

Door And Window Handles Market – Global Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/door-and-window-handles-market

 

Why Arizton?                                                   

100% Customer Satisfaction                                                   

24×7 availability – we are always there when you need us                                                   

200+ Fortune 500 Companies trust Arizton’s report                                                   

80% of our reports are exclusive and first in the industry                                                   

100% more data and analysis                                                   

1500+ reports published till date                                 

                      

Post-Purchase Benefit                                               

  • 1hr of free analyst discussion                                               
  • 10% off on customization                            

                     

About Us:                                                                                        

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports. 

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/interior-fit-out-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Interior Fit Out Market is Anticipated to Reach $89.15 Bn by 2029 | CAGR of 5.41% – Arizton

Abdominal Aortic Aneurysm Pipeline 2024: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Merck Serono, AstraZeneca, Endologix LLC, Cardinal Health

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Abdominal Aortic Aneurysm pipeline constitutes key companies continuously working towards developing Abdominal Aortic Aneurysm treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Abdominal Aortic Aneurysm Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Abdominal Aortic Aneurysm Market.

 

The Abdominal Aortic Aneurysm Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Abdominal Aortic Aneurysm Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Abdominal Aortic Aneurysm treatment therapies with a considerable amount of success over the years. Abdominal Aortic Aneurysm Key players such as – Merck Serono, AstraZeneca, Endologix LLC, Cardinal Health, Cook Medical, W. L. Gore & Associates, Inc., Medtronic, MicroPort Scientific Corporation, Artivion, Inc., Lifetech Scientific (Shenzhen) Co., Ltd., Lombard Medical, Endologix LLC, Latecba SA, Nectero Medical, Cardiatis, SA, Hangzhou Endonom Medtech Co., Ltd., and others, and others, are developing therapies for the Abdominal Aortic Aneurysm treatment

  • Abdominal Aortic Aneurysm Emerging therapies such as – Ticagrelor, Metformin Glucophage, Abdominal Aortic Aneurysm Stent Graft System, Fenestrated AlturaTM FEVAR Stent Graft, Seta Latecba Stent Grafts, Nectero EAST®, Bifurcated MFM®, and others, and others are expected to have a significant impact on the Abdominal Aortic Aneurysm market in the coming years.

  • In October 2024, Endospan, a leader in endovascular innovations for the aortic arch, has announced the completion of patient enrollment in the primary arm of its TRIOMPHE Investigational Device Exemption (IDE) clinical trial for the NEXUS® Aortic Arch Stent Graft. This study is focused on assessing the safety and effectiveness of the device in treating aortic arch conditions, including aortic arch disease and abdominal aortic aneurysms (AAA) in patients with aneurysms.

  • In January 2024, Arizona-based Nectro Medical initiated a Phase II/III trial evaluating the safety and efficacy of its endovascular aneurysm stabilisation treatment (Nectero EAST). Nectero EAST is a single-use, endovascular system made up of a dual-balloon delivery catheter and stabiliser mixture of pentagalloyl glucose (PGG). The PGG, when administered locally, can bind to elastin and collagen to potentially strengthen the aortic wall. Animal studies have shown that PGG can hinder the development of abdominal aortic aneurysm (AAA).

 

Abdominal Aortic Aneurysm Overview

Abdominal Aortic Aneurysm (AAA) is a localized enlargement of the abdominal aorta such that the diameter is greater than 3 cm or more than 50% larger than usual. It occurs when atherosclerosis or plaque buildup causes the walls of the abdominal aorta to become weak and bulge outward like a balloon.

 

Get a Free Sample PDF Report to know more about Abdominal Aortic Aneurysm Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/abdominal-aortic-aneurysm-pipeline-insight

 

Abdominal Aortic Aneurysm Pipeline Therapeutics Assessment

  • Abdominal Aortic Aneurysm Assessment by Product Type

  • Abdominal Aortic Aneurysm By Stage and Product Type

  • Abdominal Aortic Aneurysm Assessment by Route of Administration

  • Abdominal Aortic Aneurysm By Stage and Route of Administration

  • Abdominal Aortic Aneurysm Assessment by Molecule Type

  • Abdominal Aortic Aneurysm by Stage and Molecule Type

 

DelveInsight’s Abdominal Aortic Aneurysm Report covers around products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Some of the key companies in the Abdominal Aortic Aneurysm Therapeutics Market include:

Key companies developing therapies for Abdominal Aortic Aneurysm treatment are – CARDIATIS S.A., CARDINAL HEALTH, INC., COOK MEDICAL, INC., ENDOLOGIX, INC., jotec gmbh, LOMBARD MEDICAL, INC., MEDTRONIC PLC, nano endoluminal sa, TERUMO CORPORATION, W. L. GORE & ASSOCIATES, INC., and others.

 

Download Sample PDF Report to know more about Abdominal Aortic Aneurysm drugs and therapies

 

Emerging Abdominal Aortic Aneurysm Drugs and devices Under Different Phases of Clinical Development Include:

  • Metformin Glucophage: Merck Serono

  • Ticagrelor: AstraZeneca

  • Abdominal Aortic Aneurysm Stent Graft System: Lifetech Scientific

  • Fenestrated AlturaTM FEVAR Stent Graft: Lombard Medical

  • Seta Latecba Stent Grafts: Latecba SA

  • Nectero EAST®: Nectero Medical

  • Bifurcated MFM®: Cardiatis

 

Abdominal Aortic Aneurysm Pipeline Analysis:

The Abdominal Aortic Aneurysm pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Abdominal Aortic Aneurysm with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Abdominal Aortic Aneurysm Treatment.

  • Abdominal Aortic Aneurysm key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Abdominal Aortic Aneurysm Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Abdominal Aortic Aneurysm market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Abdominal Aortic Aneurysm product details are provided in the report. Download the Abdominal Aortic Aneurysm pipeline report to learn more about the emerging Abdominal Aortic Aneurysm therapies

 

Scope of Abdominal Aortic Aneurysm Pipeline Drug Insight

  • Coverage: Global

  • Key Abdominal Aortic Aneurysm Companies: Merck Serono, AstraZeneca, Endologix LLC, Cardinal Health, Cook Medical, W. L. Gore & Associates, Inc., Medtronic, MicroPort Scientific Corporation, Artivion, Inc., Lifetech Scientific (Shenzhen) Co., Ltd., Lombard Medical, Endologix LLC, Latecba SA, Nectero Medical, Cardiatis, SA, Hangzhou Endonom Medtech Co., Ltd., and others, and others

  • Key Abdominal Aortic Aneurysm Therapies: Ticagrelor, Metformin Glucophage, Abdominal Aortic Aneurysm Stent Graft System, Fenestrated AlturaTM FEVAR Stent Graft, Seta Latecba Stent Grafts, Nectero EAST®, Bifurcated MFM®, and others, and others

  • Abdominal Aortic Aneurysm Therapeutic Assessment: Abdominal Aortic Aneurysm current marketed and Abdominal Aortic Aneurysm emerging therapies

  • Abdominal Aortic Aneurysm Market Dynamics: Abdominal Aortic Aneurysm market drivers and Abdominal Aortic Aneurysm market barriers

 

Request for Sample PDF Report for Abdominal Aortic Aneurysm Pipeline Assessment and clinical trials

 

Table of Contents

1

Abdominal Aortic Aneurysm Report Introduction

2

Abdominal Aortic Aneurysm Executive Summary

3

Abdominal Aortic Aneurysm Overview

4

Abdominal Aortic Aneurysm- Analytical Perspective In-depth Commercial Assessment

5

Abdominal Aortic Aneurysm Pipeline Therapeutics

6

Abdominal Aortic Aneurysm Late Stage Products (Phase II/III)

7

Abdominal Aortic Aneurysm Mid Stage Products (Phase II)

8

Abdominal Aortic Aneurysm Early Stage Products (Phase I)

9

Abdominal Aortic Aneurysm Preclinical Stage Products

10

Abdominal Aortic Aneurysm Therapeutics Assessment

11

Abdominal Aortic Aneurysm Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Abdominal Aortic Aneurysm Key Companies

14

Abdominal Aortic Aneurysm Key Products

15

Abdominal Aortic Aneurysm Unmet Needs

16

Abdominal Aortic Aneurysm Market Drivers and Barriers

17

Abdominal Aortic Aneurysm Future Perspectives and Conclusion

18

Abdominal Aortic Aneurysm Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Abdominal Aortic Aneurysm Pipeline 2024: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Merck Serono, AstraZeneca, Endologix LLC, Cardinal Health

Food Allergy Therapeutics Market Size in the 7MM was ~USD 1,700 Million in 2023, is expected to grow by 2034, estimated DelveInsight

DelveInsight’s “Food Allergy Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the food allergy, historical and forecasted epidemiology and the food allergy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Unlock key insights into the Food Allergy Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Food Allergy Market Size

 

Key Takeaways from the Food Allergy Market Report

  • In January 2025:- ALK-Abello A/S:- This is a phase I/II, dose-escalation, multi-site trial including subjects with peanut allergy confirmed by screening double-blind, placebo-controlled food challenge. The trial is conducted in 3 parts; part 1 will determine the entry dose of the up-dosing regimen (UDR) in adults and adolescents; part 2 will characterize the tolerability of the up-dosing regimen in adults, adolescents and children; part 3 will evaluate the efficacy of 2 maintenance doses of the SLIT-tablet primarily in adolescents and children; a small number of adults may also be included.
  • DelveInsight’s analyst estimate that approximately 57.5 million Prevalent Cases of Food Allergy were found in 2023 in the 7MM.
  • The United States exhibited the highest diagnosed prevalent population of food allergy, as compared to other 7MM countries. As per DelveInsight’s estimations, the Total Prevalent Cases of Food Allergy in the US was around 33.1 million in 2023 and is projected to increase during the forecast period owing to the increasing awareness among the patient population and launch of novel therapies.
  • According to DelveInsight’s estimates, the Total Prevalent Cases of Food Allergy in EU4 and the UK were found to be ~16.9 million in 2023. Throughout the study period, it is anticipated that there will be a substantial increase in cases for all contributing countries, except for Germany, where the cases are expected to decrease. The highest proportion of Food Allergy cases was reported in Spain among the EU4 countries, while the least number of cases was found in the UK.
  • The estimates show the Total Prevalent Cases of Food Allergy in Japan was found to be around 7.4 million in 2023, which is estimated to decrease by 2034.
  • In the US, food allergy cases were classified by specific causes such as Cow Milk, Peanut, Eggs, Wheat, Treenuts, Fish, Shellfish, Soy, and Others. Shellfish accounted for the most prevalent cases, approximately 8 million, in 2023.
  • According to the analysis performed by DelveInsight’s experts, the Age-specific Cases of Food Allergy were categorized into Children, and Adults. The higher number of cases (~28 million) was accounted for by the Adults in 2023 in the US.
  • The leading Food allergy Companies such as Aimmune Therapeutics, Inc., Novartis, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc., Vedanta Biosciences, Inc., Regeneron Pharmaceuticals, Genentech, Inc., Rho Federal Systems Division, Inc., Alladapt Immunotherapeutics, Inc., Camallergy, and others.
  • Promising Food allergy Therapies such as Ligelizumab 120 mg, Dupilumab, Omalizumab, and others.

 

Stay ahead in the competitive landscape of the Food Allergy Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Food Allergy Treatment Market Size

 

Food Allergy Epidemiology Segmentation in the 7MM

  • Total Prevalent cases of Food Allergy
  • Etiology-specific cases of Food Allergy
  • Age-specific cases of Food Allergy

 

Download the report to understand which factors are driving Food Allergy epidemiology trends @ Food Allergy Prevalence

 

Food Allergy Marketed Drugs

  • Palforzia: Aimmune Therapeutics, Inc.

Approved in 2020, Palforzia is a complex biologic drug used with a structured dosing approach that builds on a century of oral immunotherapy (OIT) research. With OIT, the specific allergenic proteins are ingested initially in very small quantities, followed by incrementally increasing amounts, resulting in the ability to mitigate allergic reactions to the allergen over time. Palforiza is the first approved treatment for patients with peanut allergy. It is oral immunotherapy indicated to mitigate allergic reactions, including anaphylaxis that may occur with accidental exposure to peanuts. Palforzia is approved for use in patients with a confirmed diagnosis of peanut allergy.

 

Food Allergy Emerging Drugs

  • Ligelizumab: Novartis Pharmaceuticals

Ligelizumab (QGE031), a humanized anti-IgE antibody developed by Novartis, is a next-generation monoclonal anti-immunoglobulin E (IgE) antibody. It is also directed against Cε3, but is designed to achieve improved IgE suppression, with an equilibrium dissociation constant (KD) of 139 pM (as compared to the KD of omalizumab, ~6–8 nm). Ligelizumab’s mechanism of action involves blocking the IgE/FcεRI pathway, a key driver of the inflammatory process in CSU (chronic spontaneous urticaria), and binding with high affinity to the Cε3 domain of IgE.

 

  • Viaskin Peanut: DBV Technologies

Viaskin Peanut is the first epicutaneous immunotherapy (EPIT) in development that leverages the skin to activate the immune system and induce desensitization in peanut-allergic children. EPIT aims to target specific epidermal dendritic cells, called Langerhans cells. Pre-clinical research has shown that these cells capture antigens and migrate to the lymph node in order to activate the immune system. By delivering the allergen directly to the lymph node through the Langerhans cells, pre-clinical research has shown that EPIT activates specific regulatory T cells (Tregs) that can down-regulate the Th2-oriented reaction to the allergen.

 

Discover the future of Food Allergy Treatments with DelveInsight’s latest market report. Get expert insights and forecasts—download now! @ Food Allergy Market Drivers and Barriers

 

Food Allergy Market Outlook

Food allergy has a diverse treatment classification associated with the disease landscape. The management of food allergy primarily revolves around the utilization of Epinephrine, Anti-histamines, Steroids, Beta-2-agonists, and Palforzia as needed. Palforzia is the major revenue generator in the current treatment landscape. The market for food allergy is expected to experience positive growth with the approval of potential drugs like Ligelizumab (QGE031), Viaskin Peanut, Omalizumab, and others.

 

Food Allergy Treatment Market Landscape

Food Allergy treatment is a rapidly changing landscape, with arguably, the most significant advancement in recent years, the transition of oral immunotherapy (OIT) to clinical practice. As an innovation, OIT is a phase of rapidly increasing demand, particularly for some allergens such as peanut, egg, and milk, which have substantial evidence of efficacy. The only proven medication therapy against a food allergy is strict elimination of the offending food allergen from the diet. The primary care of treatment, including antihistamines, injectable epinephrine, and immunotherapies is prescribed to patients with mild, and moderate to severe cases of Food Allergy. Injectable epinephrine is the drug of choice for the initial management of a food-induced anaphylactic reaction. In severe anaphylaxis, ventilatory and circulatory support may be needed.

 

Explore the dynamics of the Food Allergy Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Food Allergy Ongoing Clinical Trials Analysis

 

Scope of the Food Allergy Market Report

  • Coverage- 7MM
  • Study Period- 2020-2034
  • Food Allergy Companies- Aimmune Therapeutics, Inc., Novartis, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc., Vedanta Biosciences, Inc., Regeneron Pharmaceuticals, Genentech, Inc., Rho Federal Systems Division, Inc., Alladapt Immunotherapeutics, Inc., Camallergy, and others.
  • Food allergy Therapies- Ligelizumab 120 mg, Dupilumab, Omalizumab, and others.
  • Food Allergy Market Dynamics: Food Allergy Market drivers and Food Allergy Market Barriers
  • Food Allergy Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Food Allergy Unmet Needs, KOL’s views, Analyst’s views, Food Allergy Market Access and Reimbursement

 

Table of Content

1 Key Insights

2 Report Introduction

3 Food Allergy Market Overview at a Glance

4 Methodology of Food Allergy Epidemiology and Market

5 Executive Summary of Food Allergy

6 Key Events

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Therapies

11 Emerging Drugs

12 Food Allergy: Seven Major Market Analysis

13 KOL Views

14 SWOT Analysis

15 Unmet Needs

16 Market Access

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Food Allergy Therapeutics Market Size in the 7MM was ~USD 1,700 Million in 2023, is expected to grow by 2034, estimated DelveInsight

Intraoperative Radiation Therapy Market Size, Regional Outlook, Valuable Growth Factors, Business Strategies and Future Demand

“The major players operating in the intraoperative radiation therapy market are ZEISS Group (Germany), iCAD, Inc. (US), Eckert & Ziegler (Germany), Elekta AB (Sweden), GMV Innovating Solutions (Spain)”
Browse 77 market data Tables and 33 Figures spread through 159 Pages and in-depth TOC on “Intraoperative Radiation Therapy Market by Technology (Electron IORT, Brachytherapy), Products & Services (Accelerators, Treatment Planning system, Applicators, Afterloaders, Accessories), Application (Breast, Brain, Lung Cancer) – Global Forecasts to 2025

According to the new market research report “Intraoperative Radiation Therapy Market by Technology (Electron IORT, Brachytherapy), Products & Services (Accelerators, Treatment Planning system, Applicators, Afterloaders, Accessories), Application (Breast, Brain, Lung Cancer) – Global Forecasts to 2025″, published by MarketsandMarkets™, the Intraoperative radiation therapy products market is projected to reach USD 66 million by 2025 from USD 48 million in 2020, at a CAGR of 6.4% during the forecast period.

Browse in-depth TOC on “Intraoperative Radiation Therapy Market”

77 – Tables

33 – Figures

159 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=245000083

The technological advancements such as the introduction of mobile IORT system, rising incidence of cancer, and advantages offered by IORT over conventional radiotherapy are the major factors driving the growth of the global intraoperative radiation therapy products market. Additionally, growing clinical trials exploring the use of IORT for various cancer applications is expected to offer lucrative growth opportunities to market players.

The Electron IORT segment to account for the largest share of the intraoperative radiation therapy market, by technology, in 2019

Based on technology, the intraoperative radiation therapy market is segmented into electron IORT and intraoperative brachytherapy. The electron IORT segment is expected to account for the largest share of the market in 2019. IOERT is a suitable option for patients with locally advanced or recurrent cancer such as partial breast and rectal cancer. Thus, rising target patient population, promising clinical trials, and growing R&D investments will further drive the segment growth.

The breast cancer segment, by application, is to register the highest CAGR in the market during the forecast period

Based on application, the intraoperative radiation therapy market is segmented into breast cancer, brain tumor, gastrointestinal cancer, head & neck cancer, colorectal cancer, endometrial and cervical cancer, lung cancer, and other cancers. IORT offers a reduced amount of irradiation, shorter treatment time, and lesser clinical effects on the skin, lung, and heart. Furthermore, in the case of early-stage breast cancer, IORT offers partial breast irradiation and can be used as a breast-conserving alternative to traditional lumpectomy and mastectomy. Intraoperative radiotherapy offers advantages such as high precision, better cosmetic outcomes, greater patient comfort, and cost-effectiveness. These factors driving adoption of IORT for breast cancer appication.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=245000083

North America to dominate the intraoperative radiation therapy market during the forecast period

The Intraoperative radiation therapy products market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The North American region is expected to account for the largest share of the market in 2019. The growth in this market is mainly attributed to the increasing healthcare expenditure in the region, technological advancements, and high adoption of IORT products owing to the increasing incidence of cancer.

The major players operating in the intraoperative radiation therapy market are ZEISS Group (Germany), iCAD, Inc. (US), Eckert & Ziegler (Germany), Elekta AB (Sweden), GMV Innovating Solutions (Spain), Sensus Healthcare, Inc. (US), IntraOp Medical, Inc. (US), Isoray, Inc. (US), Becton, Dickinson and Company (US), Sordina IORT Technologies (Italy), Varian Medical Systems, Inc. (US), SeeDos Ltd. (UK), IsoAid LLC (US), Ariane Medical Systems Ltd. (UK), Panacea Medical Technologies Pvt. Ltd. (India), Salutaris Medical Devices (US), Brainlab AG (Germany), RaySearch Laboratories (Sweden), REMEDI Co., Ltd. (South Korea), Merit Medical Systems, Inc. (US), among others.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=245000083

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/intraoperative-radiation-therapy-market-245000083.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Intraoperative Radiation Therapy Market Size, Regional Outlook, Valuable Growth Factors, Business Strategies and Future Demand

Pompe Disease Pipeline 2024: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Pompe Disease pipeline constitutes 15+ key companies continuously working towards developing 20+ Pompe Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Pompe Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pompe Disease Market.

 

The Pompe Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Pompe Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Pompe Disease treatment therapies with a considerable amount of success over the years. Pompe Disease Key players such as – Asklepios Biopharmaceutical, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas Gene Therapies, Spark Therapeutics, and others, are developing therapies for the Pompe Disease treatment

  • Pompe Disease Emerging therapies such as – ACTUS-101, GC301, zocaglusagene nuzaparvovec, AT2221, M 021, GYS1 Knockdown Oligonucleotide, MZE 001, AT845, AAV2/8LSPhGAA, SPK-3006, Cipaglucosidase alfa, and others are expected to have a significant impact on the Pompe Disease market in the coming years.

  • In January 2025, Aro Biotherapeutics has initiated dosing in a Phase 1b clinical trial of ABX1100, an innovative treatment for late-onset Pompe disease (LOPD), a rare genetic disorder characterized by progressive muscle weakness. This condition arises from a deficiency of alpha-glucosidase, an enzyme critical for breaking down complex carbohydrates into glucose in the small intestine. The first-in-human, open-label study aims to assess the safety and tolerability of ABX1100 in LOPD patients who are already undergoing enzyme replacement therapy (ERT).

  • In October 2024, Aro Biotherapeutics, a clinical-stage biotechnology company focused on developing effective and targeted therapies, has announced the start of the Phase 1b segment of its clinical trial for ABX1100, a promising treatment for late-onset Pompe disease (LOPD). ABX1100 utilizes siRNA therapy to specifically target muscle tissue by engaging the CD71 receptor, reducing the production of the GYS1 enzyme responsible for glycogen synthesis. The Phase 1b trial aims to enroll adults with LOPD to assess the safety and bioactivity of this innovative treatment.

  • In May 2024, Shionogi & Co., Ltd. (Osaka, Japan; CEO: Isao Teshirogi, Ph.D.) and Maze Therapeutics, Inc. (South San Francisco, California, USA; CEO: Jason Coloma, Ph.D.) have announced the completion of an exclusive global licensing agreement for MZE001. MZE001 is an investigational oral glycogen synthase 1 (GYS1) inhibitor designed to address Pompe disease by reducing the buildup of disease-causing glycogen.

 

Pompe Disease Overview

Pompe disease belongs to the ‘lysosomal storage disorders’ (LSDs) group of diseases. Within the cells, lysosomes are tiny compartments where all sorts of substances are recycled. By the action of digestive enzymes, the compounds are degraded. There are currently more than 50 different LSDs that are considered to be caused by the deficiency of one of these enzymes.

 

Get a Free Sample PDF Report to know more about Pompe Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pompe-disease-pipeline-insight

 

Route of Administration

Pompe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

 

Pompe Disease Pipeline Therapeutics Assessment

  • Pompe Disease Assessment by Product Type

  • Pompe Disease By Stage and Product Type

  • Pompe Disease Assessment by Route of Administration

  • Pompe Disease By Stage and Route of Administration

  • Pompe Disease Assessment by Molecule Type

  • Pompe Disease by Stage and Molecule Type

 

DelveInsight’s Pompe Disease Report covers around 20+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Some of the key companies in the Pompe Disease Therapeutics Market include:

Key companies developing therapies for Pompe Disease are – Spark Therapeutics, Amicus Therapeutics, Asklepios Biopharmaceutical, Audentes Therapeutics, Rocket Pharmaceuticals, Avidity Biosciences, AVROBIO, Maze Therapeutics, Denali Therapeutics, and others.

 

Emerging Pompe Disease Drugs Under Different Phases of Clinical Development Include:

  • ACTUS-101: Asklepios Biopharmaceutical

  • GC301: GeneCradle Inc

  • zocaglusagene nuzaparvovec: Astellas Gene Therapies

  • AT2221: Amicus Therapeutis

  • M 021: M6P Therapeutics

  • GYS1 Knockdown Oligonucleotide: Entrada Therapeutics

  • MZE 001: Maze Therapeutics

  • AT845: Astellas Gene Therapies

  • AAV2/8LSPhGAA: Asklepios Biopharmaceutical

  • SPK-3006: Spark Therapeutics

  • Cipaglucosidase alfa: Amicus Therapeutics

 

Download Sample PDF Report to know more about Pompe Disease drugs and therapies

 

Pompe Disease Pipeline Analysis:

The Pompe Disease pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Pompe Disease with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pompe Disease Treatment.

  • Pompe Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Pompe Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pompe Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Pompe Disease product details are provided in the report. Download the Pompe Disease pipeline report to learn more about the emerging Pompe Disease therapies

 

Pompe Disease Pipeline Market Drivers

  • Improving Healthcare Infrastructure

  • Demand for New and Effective Drugs

  • Increasing research and development in the gene therapy and enzyme replacement therapy areas

 

Pompe Disease Pipeline Market Barriers

  • Lack Of Cost-Effective Treatment

 

Scope of Pompe Disease Pipeline Drug Insight

  • Coverage: Global

  • Key Pompe Disease Companies: Asklepios Biopharmaceutical, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas Gene Therapies, Spark Therapeutics, and others

  • Key Pompe Disease Therapies: ACTUS-101, GC301, zocaglusagene nuzaparvovec, AT2221, M 021, GYS1 Knockdown Oligonucleotide, MZE 001, AT845, AAV2/8LSPhGAA, SPK-3006, Cipaglucosidase alfa, and others

  • Pompe Disease Therapeutic Assessment: Pompe Disease current marketed and Pompe Disease emerging therapies

  • Pompe Disease Market Dynamics: Pompe Disease market drivers and Pompe Disease market barriers

 

Request for Sample PDF Report for Pompe Disease Pipeline Assessment and clinical trials

 

Table of Contents

1

Pompe Disease Report Introduction

2

Pompe Disease Executive Summary

3

Pompe Disease Overview

4

Pompe Disease- Analytical Perspective In-depth Commercial Assessment

5

Pompe Disease Pipeline Therapeutics

6

Pompe Disease Late Stage Products (Phase II/III)

7

Pompe Disease Mid Stage Products (Phase II)

8

Pompe Disease Early Stage Products (Phase I)

9

Pompe Disease Preclinical Stage Products

10

Pompe Disease Therapeutics Assessment

11

Pompe Disease Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Pompe Disease Key Companies

14

Pompe Disease Key Products

15

Pompe Disease Unmet Needs

16

Pompe Disease Market Drivers and Barriers

17

Pompe Disease Future Perspectives and Conclusion

18

Pompe Disease Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pompe Disease Pipeline 2024: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas

Age-related Macular Degeneration Treatment Market Size in the 7MM was ~USD 9,840 million in 2023,is further expected to grow by 2034 | DelveInsight

DelveInsight’s ‘Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast–2034’ report deliver an in-depth understanding of the Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Age-related Macular Degeneration market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

Unlock key insights into the Age-related Macular Degeneration Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Age-related Macular Degeneration Market Size

 

Key Takeaways from the Age-related Macular Degeneration Market Report

  • In January 2025:- Hoffmann-La Roche- The main objective of the study is evaluation of the safety and tolerability of OpRegen – Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, and moderate disease progression.
  • In January 2025:- Ocular Therapeutics Inc.- A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration.
  • In January 2025:- Stealth Bio Therapeutics Inc.:- The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug.
  • In the year 2021, the total Age-related Macular Degeneration prevalent cases were approximately 51,743,361 in the 7MM, which might increase at a CAGR of 1.6% by 2034.
  • The US accounted for approximately 17,282,569 Age-related Macular Degeneration prevalent cases in the year 2021.
  • In EU-5 countries the highest number of Age-related Macular Degeneration prevalent cases was observed in Germany with 7,850,793 cases in the year 2021, followed by France.
  • Among the 7MM, Japan accounted for approximately 21% prevalent cases of AMD in the year 2021.
  • In the year 2021, the total diagnosed cases of AMD were approximately 38,807,521 cases in the 7MM. The highest number of cases were diagnosed in the US.
  • In the 7MM, the analysis of type-specific cases of AMD revealed that there were approximately 3,880,752 and 34,926,768 cases of Wet-AMD and Dry-AMD, respectively in the year 2021. These cases are expected to increase by multiple number of folds by 2034.
  • In the epidemiology model, the total age-specific cases of AMD (Dry-AMD, and Wet-AMD), are divided into age group 50-59 years, 60–69 years, 70–79 years, and ≥80 years respectively. As per the estimates by DelveInsight, the total age-specific cases of AMD are expected to increase during the forecasted period of 2022–2034.
  • In the US, the total diagnosed cases of dry AMD by age distribution were 2,175,435; 3,380,209; 3,495,783; and 2,614,307 cases for the age group 50–59 years, 60–69 years, 70–79 years, and ≥ 80 years in 2021.
  • In the US, the total diagnosed cases of dry AMD by stages were approximately 10,499,160 cases for early and intermediate dry AMD and 1,166,573 cases for advanced (geographic atrophy associated with dry AMD) in 2021. As per the analysis, stage-wise cases are also expected to by 2034.
  • In the US, the total geographic atrophy cases by visual impairment were 349,972; 583,287; and 233,315 cases for mild, moderate to severe, and patients going for surgery or having legal blindness, respectively, in 2021.
  • The leading Age-related Macular Degeneration Companies such as Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others.
  • Promising Age-related Macular Degeneration Therapies such as NG101 AAV gene therapy, Iptacopan (LNP023), VOY-101, and others.

 

Stay ahead in the competitive landscape of the Age-related Macular Degeneration Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Age-related Macular Degeneration Treatment Market Size

 

Age-related Macular Degeneration Epidemiology Insights in the 7MM

  • Total Age-related Macular Degeneration Prevalent Cases
  • Total Age-related Macular Degeneration Age-specific Cases
  • Total Age-related Macular Degeneration Diagnosed Prevalent Cases
  • Total Age-related Macular Degeneration Diagnosed Dry AMD Cases by stages
  • Total Age-related Macular Degeneration Geographic Atrophy Cases by Visual Impairment
  • Age-related Macular Degeneration Type-specific Diagnosed Prevalent Cases

 

Download the report to understand which factors are driving Age-related Macular Degeneration epidemiology trends @ Age-related Macular Degeneration Prevalence

 

Age-related Macular Degeneration Marketed Drugs

  • Eylea (aflibercept): Regeneron Pharmaceuticals

Eylea developed by Regeneron is used to treat wet-AMD. It is also used to treat diabetic eye disease and other problems of the retina. It is injected into the eye to help slow vision loss from these diseases. Eylea is the brand name for the drug called aflibercept. VEGF, a naturally occurring protein in the body triggers angiogenesis, however, in wet-AMD it is associated with abnormal blood vessel growth which causes edema leading to vision loss. Eylea blocks the growth of abnormal blood vessels in the back of the eye. At present Regeneron is conducting phase III trials to explore less frequent dosing intervals of Eylea. It is evaluating the drug for a higher dose of 8mg in wet-AMD patients after phase II trials met its primary endpoint.

 

  • Beovu (brolucizumab): Novartis

Beovu (brolucizumab) is the most clinically advanced humanized single-chain antibody fragment (scFv). Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation, and drug delivery characteristics. Beovu is the first FDA-approved anti-VEGF to offer both greater fluid resolution versus aflibercept and the ability to maintain eligible wet AMD patients on a three-month dosing interval immediately after a three-month loading phase with uncompromised efficacy.

 

  • Lucentis (ranibizumab): Roche

Lucentis (ranibizumab) is a drug used to treat wet age-related macular degeneration (AMD). It is also used to treat diabetic eye disease and other problems of the retina. It is injected into the eye to help slow vision loss from these diseases. Lucentis is the brand name for the drug, which is called ranibizumab. Ranibizumab is a humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A). It binds with high affinity to the VEGF-A isoforms (e.g. VEGF110, VEGF121, and VEGF165), thereby preventing the binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2

 

Age-related Macular Degeneration Emerging Drugs

  • OPT-302: Opthea Limited

OPT-302 (sVEGFR-3) is the first ‘Trap’ inhibitor of VEGF-C and VEGF-D designed specifically for the eye. OPT-302 blocks the two members of the VEGF family which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases, including wet AMD and DME. In combination with anti-VEGF-A therapies, OPT-302 completely shuts-down VEGFR-2 and VEGFR-3 activity and targets mechanisms of resistance and suboptimal clinical response to existing therapies. The company is currently conducting two concurrent Phase III clinical trials of OPT-302 for the treatment of wet AMD.

 

  • KSI-301: Kodiak Sciences Inc.

KSI-301 is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. Delivering potent and sustained VEGF inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes.The drug is currently being evaluated in Phase III. The readouts of the trial are expected in quarter one of 2023.

 

  • RGX-314: Regenxbio

RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. It is a potential one-time gene therapy for the treatment of wet AMD, diabetic retinopathy (DR) and other chronic retinal diseases.RGX-314 is currently being evaluated in patients with wAMD in Phase II and II/III clinical trials.

 

  • Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca

Danicopan (ALXN2040) is an oral drug developed by Alexion. It is an investigational first-in-class small-molecule inhibitor of factor D, an essential enzyme of the complement alternative pathway, which, when dysregulated, is implicated in the pathogenesis of AMD.The company is conducting a Phase II study in patients with GA secondary to AMD, and data is expected in 2023 plus.

 

  • EG-301: Evergreen Therapeutics

EG-301 is an oral dosage form that is effective and safe in animal studies with fewer side effects and is used to treat patients over 50 years of age with dry macular disease. The company is currently conducting a Phase II study to treat non-exudative (dry) AMD.

 

Discover the future of Age-related Macular Degeneration Treatments with DelveInsight’s latest market report. Get expert insights and forecasts—download now! @ Age-related Macular Degeneration Market Drivers and Barriers

 

Age-related Macular Degeneration Market Outlook

Age-related Macular Degeneration (AMD) is a chronic, progressive, and severe disease of the central retina and is the main cause of irreversible blindness in the Western world and Asia-Pacific countries. Up to date, 8.7% of the worldwide population has AMD. The wet form of the disease is responsible for more than 90% of the severe central visual acuity (VA) loss associated with AMD. The introduction of anti-VEGF intravitreal injections has opened a new therapeutic window in the management of wet AMD, thus efficiently blocking the pathophysiological process of AMD, with a restoration of retinal morphology and the maintenance of its function. In the past years, anti-VEGF injections have become the standard treatment for wet AMD, accounting for better results than the previous choices, such as photodynamic therapy (PDT) and laser photocoagulation. Currently, drugs like Lucentis (ranibizumab), Eylea (aflibercept), and Avastin (bevacizumab), work well to achieve a rapid resolution of exudative signs in most patients. Faricimab and Susvimo have also been recently approved for the treatment of Wet AMD.

 

Age-related Macular Degeneration Therapies and Companies

  • Eylea (aflibercept): Regeneron Pharmaceuticals
  • Beovu(brolucizumab): Novartis
  • Lucentis (ranibizumab): Roche
  • Vabysmo (faricimab): Roche
  • Susvimo (ranibizumab): Roche

 

Explore the dynamics of the Age-related Macular Degeneration Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Age-related Macular Degeneration Ongoing Clinical Trials Analysis

 

Scope of the Age-related Macular Degeneration Market Report

  • Coverage- 7MM
  • Study Period- 2020-2034
  • Age-related Macular Degeneration Companies- Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others.
  • Age-related Macular Degeneration Therapies- NG101 AAV gene therapy, Iptacopan (LNP023), VOY-101, and others.
  • Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration Market drivers and Age-related Macular Degeneration Market Barriers
  • Age-related Macular Degeneration Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Age-related Macular Degeneration Unmet Needs, KOL’s views, Analyst’s views, Age-related Macular Degeneration Market Access and Reimbursement

 

Table of Content

1. Key Insights

2. Report Introduction

3. Wet AMD Market Overview at a Glance

4. Dry AMD Market Overview at a Glance

5. Wet AMD Market: Future Perspective

6. Executive Summary

7. Key Events

8. Disease Background and Overview

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Drugs

12. Emerging Drugs of Wet AMD

13. Emerging Drugs of Dry AMD

14. AMD: Seven Major Market Analysis

15. Key Opinion Leaders’ Views

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Market Access and Reimbursement of Wet AMD

20. Unmet Needs

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Age-related Macular Degeneration Treatment Market Size in the 7MM was ~USD 9,840 million in 2023,is further expected to grow by 2034 | DelveInsight